← back to search

Cécile Alanio

Inserm · FR
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Cancer Cells and Metastasis, Immune Cell Function and Interaction, and CAR-T cell therapy research.
h-index
31
citations
7,528
works
144
NIH funding
primary concept
Medicine
email

Recent publications

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Nature Cancer 2024cited by 162position: middledoi
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
Cancer Cell 2024cited by 90position: middledoi
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Nature 2022cited by 897position: middledoi
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Nature Medicine 2022cited by 341position: middledoi
Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old
EBioMedicine 2022cited by 38position: middledoi
Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways
Cell Reports Medicine 2021cited by 53position: middledoi
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
Science 2020cited by 1,652position: middledoi
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
The Lancet Oncology 2020cited by 298position: middledoi
Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors
Nature Immunology 2018cited by 322position: middledoi
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines
Genome Medicine 2018cited by 205position: middledoi
Publisher Correction: Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors
Nature Immunology 2018cited by 12position: middledoi
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder
Journal of Hepatology 2017cited by 35position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Matthew L. Albert · University of Southampton2 papers (2017–2018)Darragh Duffy · Institut Pasteur2 papers (2018–2022) · 1 papers (2021–2021)Dominique Roulot · Institut Cochin1 papers (2017–2017) · 1 papers (2022–2022) · 1 papers (2021–2021)Lucile Couronné · Columbia University1 papers (2017–2017)Étienne Patin · Institut Pasteur1 papers (2018–2018)Laura A. Vella · Children's Hospital of Philadelphia1 papers (2021–2021)E. John Wherry · Translational Therapeutics (United States)1 papers (2021–2021) · 1 papers (2021–2021)Anne‐Marie Roque‐Afonso · Institut Pasteur1 papers (2017–2017)Francesco Nicoli · University of Padua1 papers (2022–2022)Olivier Hermine · Institut de Biologie Moléculaire et Cellulaire1 papers (2017–2017)Bruno Charbit · Institut Pasteur1 papers (2018–2018)Vincent Bondet · Institut Pasteur1 papers (2022–2022)Patrick Hillon · Maison des Sciences de l’Homme de Dijon1 papers (2017–2017)Christian W. Thorball · University of Lausanne1 papers (2018–2018) · 1 papers (2022–2022) · 1 papers (2022–2022)